Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 / 2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 / 2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Balstilimab (Primary) ; Zalifrelimab (Primary)
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Agenus

    • Most Recent Events

    • 02 Nov 2022 Status changed from active, no longer recruiting to completed.
    • 21 Jul 2022 This trial has been completed in Hungary (Date of the global end of the trial : 15-Jul-2022), according to European Clinical Trials Database record.
    • 20 Jul 2022 Planned End Date changed from 4 May 2023 to 15 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top